During the past decade, Albert Schweitzer Ziekenhuis conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Albert Schweitzer Ziekenhuis" are "Dyslipidemia" (3 trials), "Hypercholesterolemia" (2 trials), "Dyslipidemias" (1 trials), "Hypercholesterolemia or Combined Dyslipidemia" (1 trials) and "Primary Hypercholesterolemia" (1 trials). Many other conditions were trialed in "Albert Schweitzer Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Albert Schweitzer Ziekenhuis" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Pitavastatin" (4 trials), "Atorvastatin" (2 trials), "Placebo Statin" (1 trials), "Pravastatin" (1 trials) and "Rosuvastatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Albert Schweitzer Ziekenhuis" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Albert Schweitzer Ziekenhuis". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Albert Schweitzer Ziekenhuis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Albert Schweitzer Ziekenhuis, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".